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Background.—Optimizing patient satisfaction with their medical care and maximizing patient adherence with treatment
plans requires an understanding of patient preferences regarding education and their role in decision making when treatments
are prescribed.
Objective.—To assess the congruence between patient expectations and actual practice regarding education and decision
making at the time a triptan is prescribed.
Methods.—This multicenter cross-sectional survey was performed by headache fellow members of the American Head-
ache Society Headache Fellows Research Consortium at their respective tertiary care headache clinics. Migraine patients who
were new patients to the headache clinic and who were current triptan users (use within prior 3 months and for ≥1 year) or past
triptan users (no use within 6 months; prior use within 2 years) completed questionnaires that assessed the education they
received and their role in decision making at the time a triptan was first prescribed as well as their desire for education and
participation in decision making when a triptan is prescribed.
Results.—Consistent with patient preference, most participants received the majority of their education about the triptan
from the prescriber’s office (70.2%). In descending rank order, participants most desired to be informed about how to decide
if a triptan should be taken, when during the course of migraine a triptan should be taken, possible side effects, cost, and how
to obtain refills. Regarding side effects, most participants preferred to receive education about the most common side effects of
a triptan rather than addressing all possible side effects. Regarding triptan dosing, participants desired to be informed in
descending order of importance about taking other medications with triptans, how many doses can be taken for each migraine,
how many doses can be taken each week/month, what to do if the triptan does not work, and the triptan mechanism of action.
The vast majority of participants (92%) preferred that the decision to prescribe a triptan be a joint decision between the patient
and the provider. In actual practice, participants were not as involved in decision making as they would like to be, with patients
reporting that the prescriber was the sole decision maker 55.1% of the time. Participants had confidence in their providers
(87.7%) and generally felt they did a good job educating them about the triptan (71.1%).
Conclusions.—Based on this study, it is clear that patients prefer the shared model approach to medical decision making
in regards to the prescription of triptans. The majority of patients received education that was generally consistent with their
desires. Patients preferred that the prescribing provider be the primary source of information. The most desired educational
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topics included when/if a triptan should be taken, the number of times a triptan can be taken for a single migraine,
co-administration with other acute medications, and the most common side effects. Focusing on these topics should enhance
patient satisfaction and may improve compliance.
(Headache 2014;54:698-708)
There are 3 general models for decision making
regarding medical treatment: the paternalistic model,
the informed model, and the shared model.1 The
classic “paternalistic model” is one in which the
physician makes medical decisions for the patient
without substantial consideration of the patient’s
preferences. This model has been challenged over
time with a push toward models that take the
patient’s preferences into account. The reasons for
this shift in the approach to medical decision making
include the rise of consumerism, the passage of legis-
lation focusing on patients’ rights, and an increased
focus on the principle of autonomy. The “informed
model” involves the physician communicating infor-
mation to the patient regarding treatment options,
risks, and benefits. After being provided sufficient
information, the patient ultimately makes an
informed treatment decision based on their prefer-
ences. The “shared model” involves the physician dis-
cussing treatment options and preferences with the
patient and then both parties actively participate in
making a shared medical decision.1
Optimizing patient satisfaction and adherence
with treatment plans requires an understanding of
patient preferences regarding their role in decision
making. Furthermore, informed and shared decision
making require that patients be educated about their
treatment options. In order to maximize patients’
abilities to participate in medical decision making,
clinicians must be aware of the educational topics for
which patients desire education and must understand
how patients want their education to be delivered.
Although triptans are effective migraine-specific
acute medications,2 they are underutilized by the
migraine population.3,4 There are likely numerous
reasons for triptan underutilization, including patients
not consulting a healthcare provider for migraine,
patients not receiving a migraine diagnosis after they
present to a healthcare provider, lack of health insur-
ance, physicians not feeling that the patient’s symp-
toms are sufficiently severe to warrant a triptan, and
expense associated with filling the triptan
prescription.3-5 In addition, there are high rates of
non-adherence and discontinuation of triptans in
those patients prescribed triptans, with at least one
third discontinuing triptan use within 1 year.6 While
several studies have investigated patient satisfaction
with triptan treatment, barriers to treatment, and pre-
dictors of adherence,5,7-9 little is known about patient
satisfaction with triptan education and with their role
in decision making when a triptan is prescribed.
Patient satisfaction with their triptan and adher-
ence to triptan therapy are likely optimized when the
patient’s role in decision making matches their expec-
tations, and when the education that is provided is
consistent with the patient’s educational desires. In
clinical practice, the extent of patient participation in
the decision to initiate treatment with a triptan, as
well as the forms and extent of patient education are
highly variable. In this observational study, migraine
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patients who had used triptans were asked about their
expectations for education when a triptan is pre-
scribed and their desire to be involved in the decision-
making process regarding whether and which triptan is
prescribed. In order to assess the congruence between
patient expectations and actual practice, migraineurs
were also asked about the actual education that they
received and their actual role in the decision-making
process when the triptan was prescribed.
METHODS
This was a multicenter, prospective, cross-sectional
survey study conducted by the American Headache
Society Headache Fellows Research Consortium at ter-
tiary care academic headache specialty clinics in the
United States. Headache Fellows participating in their
headache training between July 2009 and June 2012 and
their fellowship directors served as investigators. Each
participating institution obtained Institutional Review
Board approval, and all participants completed the
informed consent process prior to study participation.
The total number of participants was based on the sum
of the number of participants each fellow could success-
fully recruit during his or her headache fellowship.
Participants were new patients to a participating
headache center who had episodic migraine or
chronic migraine according to International Classifi-
cation of Headache Disorders-II diagnostic criteria
and were either current users of triptans or had dis-
continued the use of triptans.Current use was defined
as having used a triptan within the prior 3 months and
having used triptans for at least 1 year. Discontinued
use was defined as having used a triptan within the
prior 2 years but not having used a triptan within the
last 6 months. Patients with medication overuse were
not excluded. Headache diagnoses were assigned fol-
lowing a semistructured interview performed by the
headache fellow using study questionnaires and with
oversight from headache center faculty.
Data were collected on patient perceptions
regarding the education they received about the
triptan at the time their triptan was prescribed. Ques-
tions assessed the participants’ perceptions of their
main source of education regarding the triptan, the
amount of time spent in triptan education, the format
of education delivery, the specific topics that were
discussed (eg, when to take the triptan, dosing limita-
tions, side effects, cost, refills), and the patients’
involvement in the decision-making process of being
prescribed a triptan. Additional questions were used
to assess the participants’ expectations for education
delivered within each of these aforementioned
domains at the time of triptan prescribing.
For questions regarding whether or not partici-
pants considered themselves to have received educa-
tion about a specific topic, participants chose from
the following responses: “strongly agree,” “agree,”
“neither agree nor disagree,” “disagree,” or “strongly
disagree.” For these education statements, “strongly
agree” and “agree” responses were interpreted as rep-
resenting that a subject considered themselves to have
been educated, while “neither agree or disagree,”“dis-
agree,”and“strongly disagree”were interpreted as the
subject not receiving the stated education.
All data were submitted to the principal investi-
gators at the coordinating site where data were then
entered into a secure database. All data entry were
double-checked for accuracy. Statistical analyses were
performed at the coordinating center. Descriptive sta-
tistics were used to describe subject demographics, to
compare desired vs received triptan education, and to
compare desired vs actual patient involvement in
decision making.
RESULTS
Subject Demographics.—Two hundred ninety-two
participants were enrolled in the study. This included
207 participants who continued to use triptans and 85
participants who had discontinued triptans. Average
age was 41 years (±12 years). Thirty-five participants
were male, and 257 were female. One hundred
twenty-four participants had chronic migraine, and
168 had episodic migraine. Sixty-nine participants had
migraine with aura episodes. Participants averaged
13.9 (±9.4) headache days per month and had
migraine for a mean of 22.6 years (±13 years).
Source of Education.—The main source of educa-
tion about the triptan was the prescribing provider for
66.1% of participants, followed by self-education
(17%), did not receive education (6.9%), pharmacy
(5.5%), educational materials given by the prescrib-
er’s office (3.8%), non-prescribing provider such as a
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clinic nurse (0.3%), and advertisements (0.3%). Thus,
23.9% of participants reported not receiving triptan
education or that self-education was their main
source of triptan education. On average, participants
reported that they received the following duration of
education from each source in descending order: self-
education 24.2 minutes (±65.6 minutes), prescribing
provider 10 minutes (±12 minutes), educational mate-
rials from prescriber’s office 2.4 minutes (±7.8
minutes), pharmacy 1.8 minutes (±6 minutes), non-
prescribing provider 0.7 minutes (±3.2 minutes),
and advertisements 0.4 minutes (±2.4 minutes). In
response to the question “who do you think is respon-
sible for delivering education to you about the
triptan,” 92.3% of participants ranked the prescribing
provider first (average rank 1.1 ± 0.6), followed by
pharmacy (average rank 2.7 ± 0.8), non-prescribing
provider (eg, clinic nurse) (average rank 3.1 ± 1), self-
education (average rank 3.3 ± 0.9), followed by adver-
tisements (average rank 4.8 ± 0.7) (Table 1).
Methods of Education.—77.4% (226/292) of par-
ticipants reported having received written instruc-
tions about how to take the triptan. Participants
reported wanting to receive information by oral dis-
cussion (average rank 2.2 ± 1.3, 40.2%, or 115/286
ranked oral discussion as the most desirable mode
of education), individualized written instructions
(average rank 2.4 ± 1.2, 27.3% of participants ranked
individualized written instructions as the most desir-
able mode of education), pre-printed instructions
(average rank 2.5 ± 1), package insert (average rank
3.9 ± 1.2), followed by receiving a copy of the pre-
scription (average rank 3.9 ± 1.2) (Table 2).
Education Content.—79.5% (232/292) of partici-
pants reported having received education about how
to decide if they should take the triptan. 85.6% (251/
292) of participants reported having received educa-
tion about when to take the triptan. 67.5% (197/292)
of participants reported having received education
about possible side effects from the triptans. 24.1%
(70/290) of participants received education about
how much the triptan would cost. 75.7% (221/292) of
participants reported having received education
about how to obtain refills of the triptan.
When receiving education about the triptans, par-
ticipants’ desire for specific content was ranked as
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follows, in descending order of desire: when to take
the triptan (average rank 2 ± 0.9, 27.6% of partici-
pants ranked this as most desired), how to know if
you are having a headache that can be treated with a
triptan (average rank 2.1 ± 1.3, 44.4% of participants
ranked this as most desired), potential side effects
from the triptan (average rank 2.4 ± 0.9, 21.3% of
participants ranked this as most desired), cost of the
triptan (average rank 4.2 ± 0.9), followed by how to
obtain refills of the triptan (average rank 4.3 ± 0.9)
(Table 3).
Triptan Side Effect Education.—Participants
ranked their desire to receive education about triptan
side effects in the following descending order: discus-
sion of most common side effects (average rank
2.3 ± 1.2, 36.5% of participants ranked this as most
desirable), written list of most common side effects
(average rank 2.3 ± 1, 22.2% of participants ranked
this as most desirable), complete written list of all
possible side effects (average rank 2.7 ± 1.3, 28.5%
ranked this as most desirable), discussion of all pos-
sible side effects (average rank 2.8 ± 1, 11.5% ranked
this as most desirable), no information about side
effects (average rank 4.8 ± 0.7, 1.7% ranked this as
most desirable) (Table 4).
Triptan Dosing Education.—Participants ranked
the following educational content from most desired
to least desired: how many doses of triptans you can
take for each migraine (average rank 2.3 ± 1.1, 28.0%
of participants ranked this as most desirable), taking
Table 2.—Methods of Education
Method of Education
Preferences for Method of Education
1 = Most Desirable 2 3 4 5 = Least Desirable
Oral discussion 40.2% 24.8% 13.3% 13.3% 8.4%
Individualized written instructions 27.3% 30.1% 22% 12.6% 8%
Pre-printed instructions 19.2% 28.3% 37.1% 13.6% 1.7%
Package Insert 7% 8.4% 12.9% 33.2% 38.5%
Copy of prescription 6.3% 8.4% 14.7% 27.3% 43.4%
The “Preferences for Method of Education” column demonstrates the percentage of subjects who ranked each method of education
as “most desirable” to “least desirable.”
Table 3.—Education Content
Education Content
Received
Education
Preferences for Education Content
1 = Most Desired 2 3 4 5 = Least Desired
If a triptan should be taken 79.5% 44.4% 22% 17.8% 8.4% 7.3%
When to take the triptan 85.6% 27.6% 50.3% 16.4% 4.2% 1.4%
Possible side effects from the triptans 67.5% 21.3% 21.7% 51.4% 4.5% 1%
How much the triptan would cost 24.1% 3.1% 4.2% 5.2% 46.2% 41.3%
How to obtain refills of the triptan 75.7% 3.5% 1.7% 9.1% 36.7% 49%
The “Received Education” column represents the percentage of subjects who reported that they were delivered education
regarding that specific educational component. The “Preferences for Education Content” column demonstrates the percentage of
subjects who ranked specific educational components as education that they most desired (ie, ranked 1) to least desired (ie, ranked
5).
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other medications with the triptan (average rank
2.5 ± 1.3, 31.8% of participants ranked this as most
desirable), what to do/take if the triptan does not
work (average rank 2.6 ± 1/3, 24.9% of participants
ranked this as most desirable), how many doses of
triptan you can take each week/month (average rank
3.6 ± 1.1, 4.5% of participants ranked this first), and
how the triptan works (ie, mechanism of action)
(average rank 3.9 ± 1.4, 10.7% ranked this as most
desirable).
Eighty-six percent of participants reported that
at the time of triptan prescribing, they received edu-
cation about the number of triptan doses that they
could take for a headache. 61.5% of participants
reported that at the time of triptan prescribing, they
were educated about taking other medications with
the triptan. 60.1% recalled being educated about
what to do/take if the triptan did not work. 48.3%
recalled being educated about how the triptan works
(ie, mechanism of action). 64.7% reported being edu-
cated about how many triptan doses they could take
each week/month (Table 5).
Overall, 82.5% of participants reported that they
felt educated about their triptan dosing.
Decision Making.—55.1% of participants reported
that the decision for them to treat with the triptan was
made 100% by the prescriber. 18.5% stated that the
prescriber made 75% of the decision, and they made
25% of the decision; 20.5% reported the decision was
50% prescriber and 50% them; 2.7% stated it was
Table 4.—Triptan Side Effect Education
Triptan Side Effect Education
Preferences for Side Effect Education
1 = Most Desirable 2 3 4 5 = Least Desirable
Discussion of most common side effects 36.5% 23.3% 16% 22.6% 1.8%
Written list of most common side effects 22.2% 37.2% 26.4% 13.2% 1%
Discussion of all possible side effects 11.5% 26.4% 34% 26% 2.1%
Complete written list of all possible side effects 28.5% 11.8% 21.9% 35.8% 2.1%
No information about side effects 1.7% 1.3% 1.3% 2.4% 93.1%
The “Preferences for Side Effect Education” column demonstrates the percentage of subjects who ranked specific triptan side effect
components as education that they most desired (ie, ranked 1) to least desired (ie, ranked 5).
Table 5.—Triptan Dosing Education
Triptan Dosing Education
Received
Education
Preferences for Triptan Dosing Education
1 = Most
Desirable 2 3 4
5 = Least
Desirable
Taking other medications with the triptan 61.5% 31.8% 21.8% 18.7% 18.7% 9%
How many doses of triptans you can take for each migraine 86% 28% 29.1% 27.7% 12.8% 2.4%
How many doses of triptan can you take each week/month 64.7% 4.5% 12.8% 24.2% 32.2% 26.3%
What to do/take if the triptan does not work 60.1% 24.9% 27.7% 19.7% 18.3% 9.3%
How the triptan works (mechanism of action) 48.3% 10.7% 8.7% 9.7% 18% 52.9%
The “Received Education” column represents the percentage of subjects who reported that they received education regarding that
specific educational component. The “Preferences for Triptan Dosing Education” column demonstrates the percentage of subjects
who ranked specific educational components as education that they most desired (ie, ranked 1) to least desired (ie, ranked 5).
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25% prescriber and 75% them; and 3.1% of partici-
pants reported that they were responsible for 100%
of the decision. Seven percent of participants stated
that they would prefer the decision to treat with a new
abortive medication be made 100% by the prescriber.
38.7% wanted the decision to be made 75% by the
prescriber and 25% by them; 50.9% wanted the deci-
sion to be shared equally between the prescriber and
themselves; 2.4% wanted the decision to be 25% the
prescribers and 75% theirs; and 1% wanted the deci-
sion to be completely theirs (Table 6).
Confidence and Satisfaction with Prescribing
Provider.—87.5% of participants stated that they had
confidence in the provider who prescribed the triptan
while 3.4% did not have confidence in their prescrib-
ing provider (9.2% neither agreed nor disagreed that
they had confidence in their prescribing provider).
70.9% (207/292) reported that their provider did a
good job giving them information about the triptan
while 10.8% did not think that their provider did a
good job providing them with information about the
triptan (18.2% neither agreed or disagreed that their
provider did a good job providing them with informa-
tion about the triptan).
DISCUSSION
Source and Methods of Education Delivery.—Most
participants received the majority of their education
about the triptan from the prescriber’s office in the
form of direct education from the prescriber (66.1%),
which is consistent with the patient first ranked pref-
erences that information be conveyed directly from
the prescriber in the form of an oral discussion
(40.2%). Under ideal circumstances, the prescribing
provider would be able to fully educate a patient on
all aspects of the prescribed triptan through direct
discussion with the patient. However, in actual prac-
tice, time constraints can limit the education provided
face-to-face during an appointment. As such, provid-
ing supplemental individualized written instructions
(the second most desired method of education) in
addition to an oral discussion by the prescriber would
meet the most desired preferences of the majority of
patients.
Although educating the patient is primarily the
responsibility of the prescriber, the relatively high
percentages of self-education (17%) or no education
(23.9%) may reflect the failure of package inserts,
pharmacists, and non-prescribing providers to serve
as effective second lines of patient education.
Education Content.—At least 67.5% of partici-
pants reported receiving education about if a triptan
should be taken, when a triptan should be taken,
possible side effects, cost, and how to obtain refills.
Although it is encouraging that the majority of
patients recalled receiving education about if and
when a triptan should be taken and potential triptan
side effects, these data also show that there is room
for improvement when educating patients about the
triptans.
Cost information was only received 24% of the
time. Providers might not discuss the cost of pre-
scribed medications because such information is
often difficult to access in a timely fashion because of
variation among patients’ insurance plans. Further-
more, medication cost might not be strongly consid-
ered when a provider is deciding which medication to
prescribe. In a study involving 571 physicians, effec-
tiveness of treatment was a more important factor
than high total costs in physician decision making.10 In
that study, the likelihood of a clinician choosing a
particular treatment was greater if the physician had
positive experiences with that treatment; small
patient co-payments were less important.10 As such, if
patient co-payments for a triptan are not being
Table 6.—Decision Making
Decision Making
Actual
Percentage
Patient
Preference
100% prescriber 55.1% 7%
75% prescriber and 25% patient 18.5% 38.7%
50% prescriber and 50% patient 20.5% 50.9%
25% prescriber and 75% patient 2.7% 2.4%
100% patient 3.1% 1%
The “Actual Percentage” column represents the percentage of
subjects who perceived that the decision to prescribe the
triptan was solely the prescribers, shared by the prescriber and
themselves, or solely theirs. The “Patient Preference” column
represents the percentage of subjects who preferred that deci-
sions regarding triptan therapy be made by the patient, pro-
vider, or a mix of the two.
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strongly considered by the clinician, the clinician
might be less inclined to educate the patient about
triptan cost. However, a strategy of prescribing
triptans that includes consideration of patient finan-
cial obligations may improve adherence and reduce
patient concerns. Because many of the newer elec-
tronic medical record programs include formulary
preferences specific for each patient, cost information
is likely to become increasingly more available to
prescribers, thus facilitating consideration and discus-
sion of cost at the time a triptan is prescribed.
Although physicians may choose not to spend much
time on discussing cost with their patients because it
is less desired information (Table 3), clinicians should
still consider cost when prescribing a triptan, as an
unaffordable triptan is one that a patient will be
unlikely to utilize.
Regarding side effects, most participants pre-
ferred to receive education about the most common
triptan side effects rather than addressing all possible
side effects.Addressing the most common side effects
is a patient preference that facilitates a more time
efficient discussion, and may reduce patient anxiety
that can occur while addressing multiple uncommon
side effects.
At least 60% of participants received education
about taking other medications with triptans, how
many doses can be taken for each migraine, how
many doses can be taken each week/month, and what
to do if the triptan does not work. These specific edu-
cational components cover some of the most basic
information that is required for a patient to safely and
effectively use a triptan to treat their migraine attack.
Consistent with patients’ lack of desire to discuss
triptan mechanism of action, information regarding
mechanism of action was only received about 48.3%
of the time. Although time constraint may be a factor
as to why mechanism was not addressed with a higher
frequency, some prescribers may also feel that dis-
cussing mechanism of action may overwhelm a
patient who is already receiving a large volume of
information regarding the triptan and possibly other
therapies. For patients who desire information about
mechanism of action, one approach is to include a
brief mechanism of action section in a patient instruc-
tion sheet. An alternative is to briefly include mecha-
nism of action as a segue to a discussion on dosing.
For example, explaining the triptan mechanism of
action can logically lead to a discussion regarding the
reasons why early dosing leads to better efficacy.10
Decision Making.—The vast majority of patients
(92%) preferred that the decision to prescribe a
triptan be a joint decision between the patient and the
provider. In actual practice, patients were not as
involved in decision making as they would like to be,
as patients reported that the prescriber served as the
sole decision maker 55.1% of the time. This is in con-
trast not only to the patient preferences demon-
strated in this study, but also is in contrast to the
movement toward patient centered medicine.
A survey study involving 400 physicians and 1020
of their patients demonstrated that young, healthy
female patients tended to prefer a more patient cen-
tered approach and that female physicians tended to
put more emphasis on patient preferences.11 In addi-
tion to gender, the preference of a patient to be more
involved in decision making is influenced by educa-
tion, age, and disease state. In a study by Mira and
colleagues involving 764 patients, 35.1% (268) of
patients preferred to have the last word in clinical
decisions. Age and severity of illness increased the
tendency to take a passive role in decision making.12
Prescribing a medication that the patient feels they
had a role in selecting may positively influence
patient adherence to the medication and may
decrease the chances of discontinuation.
Confidence and Satisfaction with Prescribing
Provider.—Participants had confidence in their pro-
viders (87.7%) and generally felt that their providers
did a good job educating them about the triptan
(71.1%). Clinicians who involve their patients in the
decision-making process are more likely to have sat-
isfied patients. In Krupat et al’s survey study, the most
highly satisfied patients tended to have physicians
who shared their views on the appropriate balance of
decision making between the physician and patient or
had physicians who were more patient-centered.
Patients with less patient-centered physicians were
significantly less satisfied.11
Study Limitations.—Recall bias is an important
limitation to this study. It is not possible to differen-
tiate between a subject truly not having received
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triptan education and the subject just not remember-
ing having received such education. Information
regarding medications is frequently forgotten, with
medication information being the least remembered
aspect of medical information provided to a patient
when tested 5-10 minutes following discharge from an
emergency department.13 Furthermore, a patient’s
level of health literacy may affect their recall of medi-
cation instruction. An association between inad-
equate functional health literacy and poor recall of
medication information in university-based outpa-
tient pharmacy settings has been recently docu-
mented in a pilot study.14 Patient’s health status and
number of recommendations or instructions may also
affect recall.15,16 There is an inverse relationship
between the number of recommendations given to a
patient and the proportion of recommendations they
correctly recall.16 Social support and caregiving may
play a role in patients’ recall of information.Teng et al
showed that the retention of information in an
informed consent might vary over time with the pres-
ence of social support in a population of caregivers
and patients with Parkinson’s disease.17 Asking
patients to repeat treatment recommendations may
be effective in improving patients’ recall of informa-
tion.16 Our study did not assess if patients were asked
to repeat triptan education, thus this variable was not
controlled. Free text with pictographs has been shown
to improve patient comprehension and recall of inpa-
tient discharge instructions in a small pilot study.18 We
did not assess if this method was used in patients’
education. Other factors that may affect recall include
patient expectations, age, use of medical terminology,
and medical knowledge.15,19 Reading a question or
statement regarding the presented information may
trigger more specific, complete memories, thereby
positively effecting recall.20 Therefore, the questions
in our study may have been a cue for a more appro-
priate and accurate recall of information and may
serve as a basis for improvement in provider–patient
communication.
Another limitation is that the study population is
from tertiary care headache centers so the results may
not be completely generalizable to other practices.
In future studies, subgroup analysis could be per-
formed to determine whether migraine frequency or
the presence of medication overuse headache impacts
the congruence between patient expectations and
actual practice regarding education and decision
making at the time a triptan prescription.
CONCLUSION
Based on this study, it is clear that patients prefer
the “shared model” approach to medical decision
making when a triptan is prescribed. However, the
“shared model” for decision making is currently
being underutilized. A fundamental component of
the “shared model” approach is adequate patient
education. Based on our results, the majority of
patients received education that was generally consis-
tent with their desires. Patients preferred a direct dis-
cussion with their prescribing provider as the primary
source of education. The most desired topics for dis-
cussion included when/if a triptan should be taken,
the number of times a triptan could be taken for a
single migraine attack, co-administration of the
triptan with other acute medications, and the most
common side effects. Focusing on these topics during
a direct discussion should enhance patient satisfac-
tion and may enhance compliance. Limitations of this
approach include time in the office, availability of
ancillary staff, and the patient’s ability to comprehend
information conveyed during the visit. These and
other reasons may explain why although the majority
of patients reported having received education on the
most important topics, the proportion of patients edu-
cated on each topic was far below 100%.Thus, there is
certainly room for improvement in education outside
of the headache specialist’s office, and there is need
for the specialist to provide additional triptan educa-
tion to their new patients who are already taking
triptans.
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